BG103685A - Хиноксалиндиони - Google Patents

Хиноксалиндиони Download PDF

Info

Publication number
BG103685A
BG103685A BG103685A BG10368599A BG103685A BG 103685 A BG103685 A BG 103685A BG 103685 A BG103685 A BG 103685A BG 10368599 A BG10368599 A BG 10368599A BG 103685 A BG103685 A BG 103685A
Authority
BG
Bulgaria
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Application number
BG103685A
Other languages
Bulgarian (bg)
English (en)
Inventor
Alan Stobie
Elisabeth GAUTIER
David Waite
Robert CROOK
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP1997/000995 external-priority patent/WO1997032873A1/en
Priority claimed from GBGB9715783.8A external-priority patent/GB9715783D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG103685A publication Critical patent/BG103685A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BG103685A 1997-02-27 1999-08-24 Хиноксалиндиони BG103685A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP1997/000995 WO1997032873A1 (en) 1996-03-09 1997-02-27 Quinoxalinediones
GBGB9715783.8A GB9715783D0 (en) 1997-02-27 1997-07-25 Quinoxalinediones
PCT/EP1998/001275 WO1998038186A1 (en) 1997-02-27 1998-02-24 Quinoxalinediones

Publications (1)

Publication Number Publication Date
BG103685A true BG103685A (bg) 2000-06-30

Family

ID=26070194

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103685A BG103685A (bg) 1997-02-27 1999-08-24 Хиноксалиндиони

Country Status (16)

Country Link
EP (1) EP0973766B1 (es)
JP (2) JP3588363B2 (es)
CN (2) CN1121403C (es)
AT (1) ATE282608T1 (es)
BG (1) BG103685A (es)
BR (1) BR9808126A (es)
CA (1) CA2281580C (es)
DE (1) DE69827614T2 (es)
ES (1) ES2230685T3 (es)
HR (1) HRP980104A2 (es)
HU (1) HUP0003612A3 (es)
NO (1) NO994135L (es)
NZ (1) NZ336842A (es)
SK (1) SK113399A3 (es)
TR (1) TR199902055T2 (es)
WO (1) WO1998038186A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9605027D0 (en) * 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
MY145368A (en) 2004-01-13 2012-01-31 Nissan Chemical Ind Ltd Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof
WO2005076295A1 (ja) 2004-02-06 2005-08-18 Yamaguchi University エネルギー貯蔵デバイス用電極及びその製造方法
JP2009539846A (ja) * 2006-06-06 2009-11-19 ブリストル−ミエルス スクイッブ カンパニー Ｎ−［５−［［［５−（１，１−ジメチルエチル）−２−オキサゾリル］メチル］チオ］−２−チアゾリル］−４−ピペリジンカルボキサミドの結晶形
WO2008143019A1 (en) 2007-05-17 2008-11-27 Semiconductor Energy Laboratory Co., Ltd. Triazole derivative, and light-emitting element, light-emitting device, and electronic device with the use of triazole derivative
JP5806672B2 (ja) * 2009-10-30 2015-11-10 ドメイン・セラピューティクス 新規オキシム誘導体及び代謝型グルタミン酸受容体のアロステリック調節因子としての利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194985T1 (de) * 1990-11-06 2000-08-15 Yamanouchi Pharma Co Ltd Kondensiertes pyrazinderivat
DE4217952A1 (de) * 1992-05-30 1993-12-02 Basf Ag Chinoxalin-2,3(1H,4H)-dione
GB9605027D0 (en) * 1996-03-09 1996-05-08 Pfizer Ltd Quinoxalinediones

Also Published As

Publication number Publication date
TR199902055T2 (xx) 2000-07-21
CA2281580A1 (en) 1998-09-03
NO994135D0 (no) 1999-08-26
JP2000509730A (ja) 2000-08-02
NO994135L (no) 1999-10-22
SK113399A3 (en) 2001-04-09
HUP0003612A3 (en) 2003-04-28
CN1248971A (zh) 2000-03-29
CN1121403C (zh) 2003-09-17
HRP980104A2 (en) 1999-02-28
JP3588363B2 (ja) 2004-11-10
JP2004269547A (ja) 2004-09-30
CA2281580C (en) 2003-04-22
ATE282608T1 (de) 2004-12-15
ES2230685T3 (es) 2005-05-01
DE69827614T2 (de) 2005-11-10
WO1998038186A1 (en) 1998-09-03
CN1443763A (zh) 2003-09-24
NZ336842A (en) 2000-05-26
DE69827614D1 (de) 2004-12-23
EP0973766A1 (en) 2000-01-26
HUP0003612A2 (hu) 2001-10-28
EP0973766B1 (en) 2004-11-17
BR9808126A (pt) 2000-03-08

Similar Documents

Publication Publication Date Title
KR102533094B1 (ko) 옥사디아졸 일시적 수용체 전위 채널 억제제
MX2010011358A (es) Indoles como moduladores del receptor nicotinico de acetilcolina subtipo alfa-71.
JPH05279357A (ja) アザヘテロサイクリルメチル−クロマン類
KR102150739B1 (ko) 카르바메이트/우레아 유도체
WO2008041090A1 (en) Malanin concentrating hormone receptor-1 antagonist pyridinones
US5296478A (en) 1-substituted oxindoles as cognition enhancers
JP6378404B2 (ja) 新規化合物
JP2014001227A (ja) キノロン化合物及び医薬組成物
WO2003057161A2 (en) BENZOTHIENO [3,2-c]PYRAZOLYL AND BENZOFURANO [3,2-c] PYRAZOLYL COMPOUNDS, THEIR USE IN DISEASES ASSOCIATED WITH THE 5-HT2C RECEPTOR AND INTERMEDIATE COMPOUNDS THEREOF
KR20120101551A (ko) Ｍｇｌｕｒ５ 수용체의 알로스테릭 조절자로서 바이사이클릭 티아졸
SK46793A3 (en) Regenarative melting tank and method of working
BG103685A (bg) Хиноксалиндиони
SI9520096A (sl) Derivati 2,7-substituiranega oktahidro-1H-pirido /1,2-a/ pirazina
WO2023105387A1 (en) Melanocortin 4 receptor antagonists and uses thereof
JP5769504B2 (ja) 医薬
JP2021512942A (ja) トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびｍＧｌｕ５受容体のモジュレータとしてのそれらの使用
KR100375112B1 (ko) 퀴녹살린디온
TW201103907A (en) Amide derivatives as neuropeptide Y5 receptor ligands
MXPA99007937A (es) Quinoxalinadionas
JP2002504125A (ja) ドーパミンｄ▲下４▼リガンドとしての２−アミノアルキルアミノキノリン
CZ9903052A3 (cs) Chinoxalindiony, způsoby a meziprodukty pro jejich výrobu, jejich použití, farmaceutické přípravky na jejich bázi a způsoby léčení
CA3219801A1 (en) Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor
CZ447199A3 (cs) Sloučeniny pro inhibici farnesyl­proteintransferázy, způsob jejich použití a je obsahující farmaceutické prostředky
WO2014157437A1 (ja) プロペラン誘導体